Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions
ABSTRACT Furmonertinib demonstrated potent efficacy as a newly developed tyrosine kinase inhibitor for the treatment of patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer. In vitro research showed that furmonertinib is metabolized to its active metabol...
সংরক্ষণ করুন:
| প্রধান লেখক: | , , , , , , , , |
|---|---|
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
Wiley
2025-07-01
|
| মালা: | CPT: Pharmacometrics & Systems Pharmacology |
| অনলাইন ব্যবহার করুন: | https://doi.org/10.1002/psp4.70052 |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|